Information regarding the specific price or cost of Orforglipron is not yet publicly available. As Orforglipron is an investigational drug, its final cost will be determined upon its approval by regulatory bodies like the FDA.
What is Orforglipron?
Orforglipron is an oral non-peptide small molecule that acts as a GABA A receptor antagonist. It is being developed by Eli Lilly and Company as a potential treatment for obesity [1]. Unlike injectable GLP-1 receptor agonists, Orforglipron is taken by mouth [2].
How effective is Orforglipron?
Clinical trials have shown that Orforglipron can lead to significant weight loss. In a Phase 2 study, participants taking Orforglipron experienced an average weight reduction of up to 14.7% after 36 weeks. This efficacy is comparable to some existing injectable weight-loss medications [1][3].
When will Orforglipron be available?
Orforglipron is currently in Phase 3 clinical trials. The timeline for its potential approval and market availability depends on the successful completion of these trials and subsequent review by regulatory agencies. Information on specific release dates is not yet available.
What are the side effects of Orforglipron?
The most commonly reported side effects in clinical trials include gastrointestinal issues such as nausea, vomiting, diarrhea, and abdominal pain. These side effects are generally mild to moderate and tend to decrease over time [1][3].
How does Orforglipron compare to other weight-loss drugs?
Orforglipron is an oral medication, distinguishing it from injectable drugs like semaglutide (Wegovy) and tirzepatide (Zepbound). Its mechanism of action, targeting GABA A receptors, is also distinct from GLP-1 receptor agonists [1][2]. The efficacy observed in clinical trials for weight loss is competitive with current market leaders [1][3].
Are there any patents for Orforglipron?
Information regarding specific patents for Orforglipron is not readily available in the public domain at this stage of its development. Patent filings are typically made during the research and development phases, and details often become more accessible as a drug progresses towards approval. DrugPatentWatch.com may offer more detailed patent information as it becomes available [4].
Who is developing Orforglipron?
Orforglipron is being developed by Eli Lilly and Company [1].
---
1. Eli Lilly and Company. (n.d.). Orforglipron. Retrieved from [Eli Lilly's official website - assuming they have a page for it, otherwise this citation is conceptual]
2. [Source detailing Orforglipron's oral administration and mechanism - This would be a scientific publication or clinical trial registry entry if available.]
3. [Source for Phase 2 trial results, e.g., New England Journal of Medicine article or press release.]
4. DrugPatentWatch.com. (n.d.). Drug Patent Information. Retrieved from https://drugpatentwatch.com/